ChemBriefMerck to Buy Terns in $6.7 Billion Deal
Merck & Co. agreed to acquire Terns Pharmaceuticals for $6.7 billion at $53 per share, representing a 31% premium, with the transaction expected to close within three months.
cen · 2026-03-25 00:00
1 articles
Merck & Co. agreed to acquire Terns Pharmaceuticals for $6.7 billion at $53 per share, representing a 31% premium, with the transaction expected to close within three months.